BridgeBio Pharma (BBIO) Debt Ratio (2019 - 2025)
Historic Debt Ratio for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 0.74.
- BridgeBio Pharma's Debt Ratio rose 1306.17% to 0.74 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.74, marking a year-over-year increase of 1306.17%. This contributed to the annual value of 0.8 for FY2024, which is 163.95% down from last year.
- According to the latest figures from Q3 2025, BridgeBio Pharma's Debt Ratio is 0.74, which was up 1306.17% from 0.8 recorded in Q4 2024.
- Over the past 5 years, BridgeBio Pharma's Debt Ratio peaked at 0.87 during Q2 2023, and registered a low of 0.09 during Q1 2021.
- For the 5-year period, BridgeBio Pharma's Debt Ratio averaged around 0.55, with its median value being 0.58 (2022).
- In the last 5 years, BridgeBio Pharma's Debt Ratio soared by 51825.46% in 2022 and then tumbled by 3732.33% in 2024.
- Over the past 5 years, BridgeBio Pharma's Debt Ratio (Quarter) stood at 0.43 in 2021, then skyrocketed by 62.65% to 0.69 in 2022, then increased by 18.12% to 0.82 in 2023, then dropped by 1.64% to 0.8 in 2024, then fell by 7.72% to 0.74 in 2025.
- Its last three reported values are 0.74 in Q3 2025, 0.8 for Q4 2024, and 0.66 during Q3 2024.